Buffalo / Houston / Oklahoma City / Lyon / Birmingham / Baltimore / New York / Phoenix / San Juan / /
Company
Ovarian Cancer National Alliance / Novartis / Amgen / Southwestern Oncology Group / Celgene / Goldman / Eastern Cooperative Oncology Group / J&J / Elsevier Inc. / Genentech / Qiagen / Oxford University Press / Merck / Gynecologic Cancer Intergroup / Astra / Abbvie Pharmaceuticals / 3rd International Gynecologic Cancer Intergroup / Fleming / Johnson & Johnson / Lilly / Gynecologic Oncology Group / Pearson / Cannistra SA. / Mariotto AB / /
Continent
Europe / /
Country
Puerto Rico / Netherlands / France / United States / Columbia / /
Event
Business Partnership / FDA Phase / /
Facility
Montefiore Medical Center / University of Alabama / USA John Hopkins Kimmel Cancer Center / Columbia University / MD Anderson Cancer Center / Huang HQ / Winthrop University Hospital / New York Presbyterian Medical Center / Fort Washington Ave. / The University of Texas / National Cancer Institute / University of Arizona Cancer Center / Albert Einstein College of Medicine / University of Mississippi Medical Center / /
IndustryTerm
contemporary management / treatment of ovarian cancer / biologics license applications / ovarian cancer therapy / treatment of recurrent disease / imaging / Therapy for advanced stage cancer / treatment for ovarian cancer / ovarian cancer therapeutics / biological products / tumor profile technologies / supplemental applications / treatment of anxiety in patients with cancer / real-time informatics / ovarian cancer care / web-based survey tool / therapies for ovarian cancer / treatment of epithelial ovarian cancers / treatment of patients with advanced ovarian cancer / objective dynamic imaging tools / Treatment for metastatic ovarian cancer / /
MedicalCondition
recurrent ovarian cancer / ovarian cancers / Ovarian cancer / significantly delay disease / relative ovarian cancer / residual disease / endpoints ovarian cancer / such / contemporary ovarian cancer / endometrioid carcinomas / ovarian low-grade serous carcinoma / advanced epithelial ovarian cancer / platinum-sensitive recurrent ovarian carcinoma / serous cancers / visible disease / sensitive ovarian cancer / quickly available Tumor / early stage disease / IV ovarian cancer / epithelial ovarian cancer / recurrent disease / advanced stage disease / tumor / advanced-stage ovarian cancer / III recurrent ovarian cancer / advanced cancers / Cancer / Gynecological Cancer / gross residual disease / ovarian neoplasms / primary peritoneal cancer / metastatic ovarian cancer / diseases / fallopian tube cancer / stable disease / based tumor / ovarian cancer patients experiencing disease / high-grade serous cancers / II cancer / tumor shrinkage / advanced disease / III ovarian carcinoma / therapeutically responsive tumors / advanced ovarian cancer / solid tumors / testicular cancer / novel cancer / confirm disease / heterogeneous disease / Carcinoma / J Cancer / III epithelial ovarian cancer / II lung cancer / MS / advanced stage cancer / epithelial ovarian cancers / ovarian carcinoma / advanced ovarian carcinoma / advanced stage ovarian cancer / disease / III ovarian cancer / longitudinal tumor / platinum resistant disease / rapid cancer / pain / Jemal A. Cancer / Non-US recurrent ovarian cancer PFS / platinum-sensitive recurrent ovarian cancer / /
MedicalTreatment
surgery / cancer therapy / chemotherapy / counseling / chemotherapies / intraperitoneal chemotherapy / cancer therapeutics / adjuvant therapy / /
Organization
Creighton University School of Medicine / National Alliance / American Society of Clinical Oncology / Columbia University / New York / Albert Einstein College of Medicine / Mississippi Medical Center / FDA / Oncologic Drugs Advisory Committee / European Union / Oxford University / American Association for Cancer Research / University of Alabama at Birmingham / University of Texas / National Cancer Institute / US NDA / University of Arizona Cancer Center / Food and Drug Administration / Speakers Bureau / Winthrop University Hospital / USA John Hopkins Kimmel Cancer Center / Society of Gynecologic Oncology / University of Mississippi / European Medicines Agency / Division of Gynecologic Oncology / Montefiore Medical Center / FDA Advisory Committee / Center for Drug Evaluation and Research / New York Presbyterian Medical Center / International Agency for Research / /
Person
Bradley J. Monk / Jessica Oldham / Shih IeM / Ellen Sullivan / Mark H. Einstein / Robert S. Mannel / Sharee A. Umpierre / Ann Oncol / Robert L. Coleman / Ronald Alvarez / Thomas J. Herzog / James Thigpen / Mark F. Brady / Jeannine A. Villella / Ronald D. Alvarez / Deborah K. Armstrong / Silver Spring / /
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper